FDA Approves Ionis' Zanvastro (Zilganersen) as the First Disease-Modifying Therapy for Alexander Disease

FDA Approves Ionis' Zanvastro (Zilganersen) as the First Disease-Modifying Therapy for Alexander Disease

On September 3, 2026, the U.S. Food and Drug Administration (FDA) approved Ionis Pharmaceuticals' Zanvastro (zilganersen) injection for the treatment of pediatric and adult patients with Alexander disease (AxD). This landmark decision, coming more than two weeks ahead of its September 22, 2026 PDUFA action date, establishes Zanvastro as the first-ever disease-modifying therapy for this ultra-rare, progressive, and often fatal neurological disorder.¹

Disease Background and Mechanism

Alexander disease is an extremely rare leukodystrophy affecting approximately 1 in 1 to 3 million people worldwide. It is driven by mutations in the glial fibrillary acidic protein (GFAP) gene, which lead to the overproduction and toxic accumulation of GFAP in astrocytes. Over time, this astrocyte dysfunction damages myelin and neurons, causing progressive motor and cognitive decline, loss of independence, and the inability to control muscles for swallowing or purposeful movements. It typically leads to death within 14 to 25 years of symptom onset.

Zanvastro is an RNA-targeted antisense oligonucleotide (ASO) designed to bind to GFAP mRNA and reduce the production of the abnormal GFAP protein before it can accumulate. It is administered quarterly as a 50 mg intrathecal (IT) injection.

Clinical Trial Evidence

The FDA approval was supported by a global, randomized, double-blind, controlled Phase I-III study (NCT04849741) that enrolled 54 participants aged 1.5 to 53 years across 13 sites in eight countries, randomized 2:1 to receive Zanvastro or control for a 60-week double-blind period.

• Motor Stabilization in Patients Aged 5+: Zanvastro met its primary endpoint, demonstrating statistically significant and clinically meaningful stabilization of gait speed on the 10-Meter Walk Test compared to the control group at Week 61, with a least square mean difference of 33.3% (p=0.041). While untreated patients saw a 33% decline in walking speed, treated patients remained stable.
• Improvement in Pediatrics (Ages 2–4): An open-label substudy in patients under 2 years of age demonstrated improvements in gross motor function as assessed by the Gross Motor Function Measure-88 (GMFM-88) compared to a declining control group.
• Safety: Treatment-emergent adverse events (TEAEs) were mostly mild-to-moderate, transient, and occurred on the day of dosing. A warning for aseptic (chemical) meningitis is included in the prescribing information, which occurred in some patients and required temporary dose interruption or dexamethasone pretreatment.

Commercial Launch and Regulatory Incentives

In conjunction with the approval, the FDA awarded Ionis a Rare Pediatric Disease Priority Review Voucher (PRV). Ionis plans to commercialize Zanvastro independently, marking its first independent neurology launch. The company has priced the therapy at $285,000 per dose, resulting in an annual maintenance cost of approximately $1.14 million. Peak sales are projected to exceed $100 million.

"Today's approval of ZANVASTRO begins a new chapter for people living with Alexander disease and their families, who have long faced this relentlessly progressive and often fatal disease with no treatment options... This transformative approval also marks our first independent launch from our industry-leading neurology pipeline and underscores the power of our RNA-targeted technology to address serious neurological diseases without adequate treatment options." — Brett P. Monia, Ph.D., Chief Executive Officer, Ionis Pharmaceuticals

"The FDA approved the drug, Zanvastro, for use in children and adults after a pivotal trial showed that walking speed, a common measure of motor function in neurologic disease, stayed stable in treated patients while those in the control group saw a 33% decline." — STAT News (September 3, 2026)